Prevduo, a Neostigmine-Glycopyrrolate Combo Product, Now Available
2024-02-18
Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) has been made available by Endo for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (eg, bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration.
Prevduo contains a fixed-dose combination of neostigmine, a cholinesterase inhibitor and glycopyrrolate, an antimuscarinic agent. Both drugs have been previously approved as single agent products; the new combination removes the need for 2 syringe preparations and administrations.
“This is the latest way we’re addressing operational and clinical challenges in order to support patient care,” said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. “With 2 medications in one ready-to-use syringe, Prevduo reduces complexity and increases efficiency for hospitals and health care providers.”
Prevduo is supplied as a solution containing 3mg/3mL of neostigmine methylsulfate and 0.6mg/3mL of glycopyrrolate (1mg/mL of neostigmine methylsulfate and 0.2mg/mL of glycopyrrolate) in a single-dose 3mL prefilled syringe. The product will be distributed in the US by Slayback Pharma LLC.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。